GENFIT
Develops therapies and diagnostics for patients with rare and severe liver diseases.
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
Description
GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-24 22:10 |
GENFIT annonce son calendrier financier pour 2023
|
French | 110.9 KB | ||
| 2023-01-24 22:10 |
GENFIT Announces 2023 Financial Calendar
|
English | 149.4 KB | ||
| 2023-01-05 22:10 |
GENFIT annonce sa participation aux prochaines conférences investisseurs
|
French | 108.4 KB | ||
| 2023-01-05 22:10 |
GENFIT to Participate in Upcoming Investor Conferences
|
English | 128.7 KB | ||
| 2022-11-17 22:10 |
GENFIT : Le Pipeline Day met en valeur un portefeuille de produits diversifié d…
|
French | 293.9 KB | ||
| 2022-11-17 22:10 |
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver D…
|
English | 208.2 KB | ||
| 2022-11-10 22:10 |
GENFIT : Information financière du troisième trimestre 2022
|
French | 186.3 KB | ||
| 2022-11-10 22:10 |
GENFIT Reports Third Quarter 2022 Financial Information
|
English | 656.5 KB | ||
| 2022-10-25 22:10 |
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic…
|
English | 228.1 KB | ||
| 2022-10-25 22:10 |
GENFIT annoncera à l’AASLD Liver Meeting® des résultats convaincants pour NIS2+…
|
French | 210.4 KB | ||
| 2022-09-29 22:10 |
GENFIT annonce la signature du Share Purchase Agreement et la finalisation de l…
|
French | 152.9 KB | ||
| 2022-09-29 22:10 |
GENFIT Announces Signature of the Share Purchase Agreement and the Completion o…
|
English | 147.4 KB | ||
| 2022-09-28 22:10 |
Genfit - Rapport d'Activité et Financier Semestriel 2022 - Rapport des Commissa…
|
French | 2.1 MB | ||
| 2022-09-28 22:10 |
GENFIT : Résultats financiers du premier semestre 2022 et point sur les activit…
|
French | 341.2 KB | ||
| 2022-09-28 22:10 |
GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate U…
|
English | 362.0 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GENFIT
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
Peer Companies
